Relevant disclosures attached
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fortis Healthcare Limited's Board approved audited consolidated financial results for Q4 and FY ended March 31, 2026. Revenue from operations grew 17.3% to ₹912,784 Lacs from ₹778,275 Lacs in the previous year. EBITDA increased 29% to ₹213,564 Lacs, while net profit rose 31.5% to ₹106,419 Lacs from ₹80,938 Lacs. EPS improved from ₹10.26 to ₹13.80. The Board recommended a final dividend of ₹1 per equity share. Statutory auditors B S R & Co. LLP issued an unmodified opinion. The audit report includes an Emphasis of Matter regarding ongoing SFIO investigation on alleged improper transactions and non-compliances relating to the period prior to 2018, and a Supreme Court order directing forensic audit of transactions with RHT Health Trust.
Strong financial performance with 31.5% PAT growth and improved margins is positive for shareholders. However, the Emphasis of Matter on ongoing regulatory investigations into historical transactions represents a contingent liability risk that investors should monitor.